Candia, Jimboy M.
HRN: 20-48-83 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/15/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/15/2023
01/22/2023
IVTT
165mg
Q24
PCAP
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes